CLAIMS

1. A use of an inhaled composition in a manufacture of a medicament for a treatment of at least one of asthma and obstructive respiratory disorder, characterized in that the inhaled composition comprises:

   an effective amount of beta-2 agonist; and

   an effective amount of corticosteroid, wherein the medicament is for use before sleeping and after waking up.
2. The use as claimed in claim 1, characterized in that the inhaled composition further comprises a pharmaceutically acceptable carrier.
3. The use as claimed in claim 1 or 2, characterized in that the inhaled composition is an inhaled aerosol composition.
4. The use as claimed in any one of claims 1 to 3, characterized in that the beta-2 agonist is one selected from a group consisting of Albuterol, Fenoterol, Procaterol, Terbutaline, Albuterol sulfate, Procaterol HCl, Fenoterol hydrobromide, Terbutaline sulphate and a combination thereof.
5. The use as claimed in any one of claims 1 to 4, characterized in that the corticosteroid is one selected from a group consisting of Budesonide, Fluticasone, Mometasone, Ciclesonide, Beclomethasone, Triamcinolone, Fluticasone propionate, Beclomethasone dipropionate, Triamcinolone Acetonide and a combination thereof.
6. The composition as claimed in claims 1 to 5, characterized in that the ratio of the beta-2 agonist and the corticosteroid is 1:2 w/w% to 1:70 w/w%.
7. A use of an inhaled composition in a manufacture of a medicament for a treatment of at least one of asthma and obstructive respiratory disorder, characterized in that the inhaled composition comprises:

   an effective amount of beta-2 agonist; and

   an effective amount of corticosteroid, wherein the medicament is used before sleeping and after waking up.

CLAIMS

1. A use of an inhaled composition in a manufacture of a medicament for a treatment of at least one of asthma and obstructive respiratory disorder, characterized in that the inhaled composition comprises:

   an effective amount of Procaterol; and

   an effective amount of Budesonide, wherein the ratio of the Procaterol and Budesonide is 1:2 w/w% to 1:70 w/w%.

2. The use as claimed in claim 1, characterized in that the inhaled composition further comprises a pharmaceutically acceptable carrier.

3. The use as claimed in claim 1 or 2, characterized in that the inhaled composition is an inhaled aerosol composition.

4. The use as claimed in any one of claims 1 to 3, characterized in that the ratio of Procaterol and Budesonide is 1:5 w/w% to 1:60 w/w%.